KOLIBRI

We are on a mission to make cell and gene therapies accessible and affordable for all. To that end, we have developed a new and unique way to grow mammalian cells using acoustic waves.

Whilst extremely promising to cure incurable diseases ranging from cancer to neuro-degenerative diseases, cell and gene therapies are facing major biomanufacturing limits with production costs as high as 2m$/patient.

Showing 100x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development and manufacturing unlock patient access to these promising therapies.

Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly.

Kolibri is a deeptech founded in 2021 and backed by leading deeptech investors, including SOSV and Entrepreneur First.